03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
20:40 , Feb 23, 2017 |  BC Innovations  |  Translation in Brief

Just the essentials

A team led by University of Texas MD Anderson Cancer Center President Ronald DePinho has developed a method of scouring cancer genome databases for new targets by looking for what he calls "the ghosts of...
19:08 , Feb 22, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Bioinformatics screens A bioinformatics method of screening for synthetically lethal gene pairs could help identify new targets to treat cancer. The method involved scanning cancer databases to identify pairs of genes for which deletion of...
07:00 , May 21, 2001 |  BC Week In Review  |  Clinical News

BRCA1 and BRCA2 breast and ovarian cancer genes regulatory update

Myriad Genetics Inc. (MYGN), Salt Lake City, Utah   Product: BRCA1 and BRCA2 breast and ovarian cancer genes   Business: Pharmacogenetics   MYGN received eight patents covering the use of BRCA1 and BRCA2 to develop therapeutic...
08:00 , Nov 13, 2000 |  BC Week In Review  |  Company News

Myriad Genetics other research news

MYGN said it has identified 6 targets involved in the regulation of lipid metabolism that are part of the Coronary Heart Disease 1 (CHD1 or ZNF202) gene pathway, using its ProNet protein interaction technology. MYGN...
08:00 , Mar 16, 1998 |  BC Week In Review  |  Company News

Myriad Genetics, Novartis Pharmaceuticals Corp. deal

MYGN received a $500,000 milestone from partner Novartis for its discovery of CHD1, a gene associated with cardiovascular disease (see Technology Briefing, BioCentury Part I). Myriad Genetics Inc. (MYGN), Salt Lake City, Utah   Novartis Pharmaceuticals...
08:00 , Mar 16, 1998 |  BioCentury  |  Tools & Techniques

The10 percent solution

Myriad Genetics Inc. and partner Novartis Pharmaceuticals Corp. have discovered a gene, called Coronary Heart Disease 1 (CHD1), correlated with cardiovascular disease in humans that the company says could lay the basis for a new...